New COO, CCO, and CIO Bring Proven Operational, Commercial, and Digital Expertise to Enhance Allucent’s Biopharma Partnerships Across Its Expanding Global Portfolio
CARY, N.C., September 3, 2025 – Allucent, a global, science-centric CRO focused on partnering with small and mid-sized biopharmaceutical innovators, today announced the expansion of its executive team with three proven industry leaders. Patrick Phillips has joined as chief operating officer (COO), Rachel Page as chief commercial officer (CCO), and Nate Thompson as chief information officer (CIO). Their combined decades of CRO and biopharma leadership and proven specialized expertise further strengthen Allucent’s ability to scale, innovate, and deliver unique value for small and mid-sized companies, driving tomorrow’s breakthrough therapies.
In today’s competitive life sciences market, speed, precision, and informed decision-making are critical. Allucent’s approach — global reach, nimble methodology, and A-Team drug development experts — helps biopharma businesses advance programs efficiently, reduce risk, and maximize value from the start. The company’s new appointments further strengthen its operational delivery and trusted partnerships with its clients.
“I’m thrilled to welcome Patrick, Rachel, and Nate to Allucent as we enter our next chapter,” said Paula Brown Stafford, CEO of Allucent. “They bring the right mix of expertise and passion at exactly the right time. Each has a proven track record in high-growth CRO and/or biopharma environments and a drive to advance the transformative science coming from small and mid-sized biopharmaceutical companies. Their leadership will accelerate our momentum, strengthen our capabilities, and reinforce Allucent’s position as the partner of choice for biopharma innovators working to bring new therapies to patients.”
Patrick Phillips, BSc (Hons), D.Phil. – chief operating officer
As COO, Patrick Phillips will lead Allucent’s global operations, ensuring scalability, quality, and efficiency across all business units. He brings deep expertise in operational excellence across drug development and scientific services, driving seamless execution and supporting Allucent’s global portfolio of client partnerships.
Phillips has more than 30 years of experience in biopharma and CRO leadership, successfully driving global operational transformations, large-scale growth, and strategic acquisitions. He previously served as CEO of Health Decisions (acquired by Premier Research), where he led the specialty CRO in significantly increasing its enterprise value. He also held senior roles at Boehringer Ingelheim, ICON, Array BioPharma, and GlaxoSmithKline.
Rachel Page – chief commercial officer
As CCO, Rachel Page will lead Allucent’s commercial strategy, focusing on fostering strong partnerships and delivering tailored solutions that drive measurable impact and address evolving client needs. She brings extensive experience scaling commercial operations, modernizing go-to-market strategies, and building high-performing teams in CRO and life sciences organizations.
Page served as CCO at Veristat and CTI and as group vice president at Clario, overseeing global business development and commercial organizations. She is recognized for scaling high-performing teams and forging strong client partnerships across therapeutic areas, including oncology, rare diseases, cell and gene therapy, and neuroscience.
Nate Thompson – chief information officer
As CIO, Nate Thompson will drive Allucent’s global technology and AI strategy, advancing data-driven decision-making, efficiency, and innovative client solutions. He brings extensive experience implementing digital platforms and AI-enabled systems to accelerate drug development and enhance performance across global teams.
Thompson has over two decades of leadership in life sciences technology. He held positions at companies including United BioSource, Premier Research, and Syneos Health, where he spearheaded AI initiatives, enterprise architecture design, real-time data platforms, and clinical system integrations that shortened time-to-market and reduced costs.
About Allucent
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges faced by biopharma and government clients. A global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a range of therapeutic areas, Allucent brings more than 30 years of experience in over 60 countries. With an A-Team of former regulators, leading scientists, and clinical experts, Allucent’s individualized partnership approach delivers deep insights and hands-on expertise to help clients navigate the complexities of bringing innovative treatments to patients. Learn more at Allucent.com.
MEDIA CONTACT:
Heather Shea heather.shea@catalyticagency.com
Share This
